TBL2: A Potential Drug Target and Biomarker for Chronic Pain (G26608)

Target Name: TBL2

NCBI ID: G26608

TBL2

TBL2: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:

Transducin beta-like protein 2 (TBL2) is a highly expressed gene in various tissues, including the central nervous system, and has been implicated in pain modulation. Although several studies have investigated the function of TBL2, its precise role in pain modulation and its potential as a drug target or biomarker remain unclear. In this article, we will review the current understanding of TBL2 function, its potential as a drug target, and its potential as a biomarker for chronic pain.

Introduction:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The inability to alleviate chronic pain can lead to significant morbidity and mortality, making it a priority to identify new treatments and biomarkers. One of the promising protein candidates for pain modulation is TBL2, a member of the transducin family that has been shown to participate in a variety of physiological processes.

History of TBL2:

TBL2 was first identified in the mouse genome in the late 1990s by researchers led by Dr. Xujiong Ye. They demonstrated that TBL2 was highly expressed in various tissues and that it was involved in the modulation of pain sensitivity. Since then, several studies have confirmed the function of TBL2 in pain modulation, including its role in neuropathic pain and its potential as a drug target.

Function of TBL2:

TBL2 is involved in the modulation of pain perception and sensitivity to pain stimuli. Several studies have shown that TBL2 is involved in the neurotransmitter release and modulation of pain signals. For example, TBL2 has been shown to modulate the release of endogenous opioids, such as enkeji, a potent opioid involved in pain modulation. Additionally, TBL2 has been shown to modulate the activity of GABA-Aergic neurons, which are involved in the inhibition of pain signals.

Drug Target Potential:

TBL2 has been identified as a potential drug target for chronic pain due to its involvement in pain modulation. The precise mechanism of TBL2's involvement in pain modulation is not yet fully understood, but it is thought to involve the modulation of pain signals through the modulation of neurotransmitter release and the activity of specific neurons.

Biomarker Potential:

TBL2 has also been suggested as a potential biomarker for chronic pain due to its expression in various tissues, including the central nervous system. The exact role of TBL2 as a biomarker for chronic pain is not yet fully understood, but it is thought to be involved in the modulation of pain sensitivity and the release of endogenous opioids.

Conclusion:

TBL2 is a promising protein candidate for pain modulation and has been shown to be involved in the modulation of pain perception and sensitivity to pain stimuli. Its potential as a drug target and biomarker for chronic pain is being investigated further, and future studies are needed to fully understand its role in pain modulation.

Keywords: Transducin beta-like protein 2, chronic pain, pain modulation, drug target, biomarker.

Protein Name: Transducin Beta Like 2

The "TBL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets